Core Insights - Rongchang Biologics (688331) reported a significant increase in revenue for the first three quarters of 2025, achieving 1.72 billion yuan, which represents a year-on-year growth of 42.27%. However, the company recorded a net loss of 551 million yuan [1]. Financial Performance - The company's revenue for the first three quarters reached 1.72 billion yuan, marking a 42.27% increase compared to the previous year [1]. - The net profit attributable to the company was a loss of 551 million yuan [1]. Strategic Developments - The increase in product sales revenue was attributed to a substantial rise in sales and an optimization of the company's research and development pipeline, leading to a decrease in R&D expenses [1]. - Rongchang Biologics entered into a licensing agreement with Vor Bio, allowing Vor Bio exclusive rights to develop and commercialize the proprietary drug Tai Tasi Pu outside of Greater China, which resulted in reduced overseas clinical costs for the company [1].

Group 1 - Rongchang Biopharmaceutical (SH 688331) announced on October 30 that its 29th meeting of the second board of directors will be held on October 30, 2025, to review the proposal for the "2025 Q3 Report" [1] - For the year 2024, the revenue composition of Rongchang Biopharmaceutical is 99.61% from the pharmaceutical manufacturing industry and 0.39% from other businesses [1] - As of the report date, the market capitalization of Rongchang Biopharmaceutical is 50 billion yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 承董事會命 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 王威東先生 核查意见 华泰联合证券有限责任公司关于 荣昌生物制药（烟台）股份有限公司 2026-2028 年度日常关联交易预计的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为荣昌生物制药（烟台）股份有限公司（以下简称"荣昌生物"或"公司"） 首次公开发行股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上 市保荐业务管理办法》《上海证券交易所科创板股票上 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 承董事會命 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 海外監管公告 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 王威東先生 中國煙台 2025年10月30日 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《公 司 2025 年第三季度报告》。 本议案已经公司董事会审核委员会会议审议通过。 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 ...

Core Insights - Rongchang Biologics (09995) reported a revenue of approximately 1.72 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 42.27% [1] - The net loss attributable to shareholders narrowed to approximately 551 million yuan, a reduction of 48.6% compared to the previous year [1] - The basic loss per share was reported at 1.01 yuan [1] Revenue Performance - The significant increase in product sales revenue contributed to the overall revenue growth [1] - The company optimized its research and development pipeline, leading to a decrease in various R&D expenditures [1] Licensing Agreement - Rongchang Biologics entered into a licensing agreement with Vor Bio, granting them exclusive rights to develop and commercialize the proprietary drug Tai Tasi Pu outside of Greater China [1] - This agreement resulted in reduced overseas clinical costs for Tai Tasi Pu, further contributing to the decrease in net loss for the year [1]

Core Insights - Rongchang Bio reported a revenue of 622 million yuan for Q3 2025, representing a year-on-year growth of 33.13% [1] - The net profit attributable to shareholders for Q3 2025 was a loss of 101 million yuan [1] - For the first three quarters of 2025, the company achieved a total revenue of 1.72 billion yuan, marking a year-on-year increase of 42.27% [1] - The net profit attributable to shareholders for the first three quarters was a loss of 551 million yuan [1]

每经AI快讯，10月30日，荣昌生物(09995.HK)在港交所发布公告称，2025年前三季度营收约17.20亿 元，同比增42.27%；亏损约5.51亿元，同比降48.55%。主要是由于产品销售收入大幅度增加，另公司研 发管线优化，各项研发支出下降，加之公司与美国Vor Bio公司订立许可协议约定将具有自主知识产权 的泰它西普有偿许可给美国 VorBio 公司，由此导致泰它西普海外临床费用减少，进而导致本年亏损大 幅下降。 （文章来源：每日经济新闻） ...

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2025-044 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 关于预计 2026-2028 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：是 日常关联交易对上市公司的影响：本次关联交易属于公司日常生产经营 业务，遵循了平等、自愿、等价、有偿的原则，交易条件及定价合理、公允，不 存在损害公司及全体股东合法权益，特别是中小股东利益的情形，不会影响公司 的经营独立性，公司不会因本次日常关联交易而对关联人形成依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 10 月 30 日，荣昌生物制药（烟台）股份有限公司（以下简称"公 司"）召开第二届董事会第二十九次会议审议通过了《关于预计 2026-2028 年度 日常关联交易的议案》，关联董事分别回避了相关关联交易的表决，此议案获得 出 ...

智通财经APP讯，荣昌生物(09995)公布2025年前三季度业绩，营业收入约17.2亿元，同比增长42.27%; 归属于上市公司股东的净亏损约5.51亿元，同比收窄48.6%;基本每股亏损1.01元。 公告称，净亏损减少主要是由于产品销售收入大幅度增加，另公司研发管线优化，各项研发支出下降， 加之公司与美国 Vor Bio 公司订立许可协议约定将具有自主知识产权的泰它西普有偿许可给美国 VorBio 公司，美国 Vor Bio 公司将获得在除大中华区以外的全球范围内开发和商业化的独家权利，由此导致泰 它西普海外临床费用减少，进而导致本年亏损大幅下降。 ...

Financial Performance - The company achieved a revenue of 1.72 billion yuan in the first three quarters, representing a year-on-year increase of 42.27% driven by strong sales of its core products, Taitasip and Vedisimab [2][5] - The net loss attributable to shareholders narrowed significantly to 551 million yuan from 1.071 billion yuan in the same period last year, indicating a substantial reduction in losses [2][5] - Operating cash flow turned positive with a net amount of 217 million yuan, compared to a negative 835 million yuan in the previous year, reflecting improved cash generation capabilities [2][5] Core Business Progress - Sales of the main products, Taitasip and Vedisimab, saw significant growth, contributing to the overall revenue increase [2][5] - The company signed an overseas licensing agreement with VorBio, which not only brought in cash flow but also reduced overseas R&D expenses [2][7] R&D and Cost Structure - R&D investment decreased to 891 million yuan, down 22.79% year-on-year, with its proportion of revenue falling to 51.78% from 86.4% in the previous year, indicating a focus on high-potential projects [2][6] - Sales expenses increased by 32.15% to 823 million yuan, reflecting a heightened marketing effort to capture market share, while management expenses slightly decreased to 216 million yuan [2][6] Asset and Liability Structure - As of the end of the third quarter, total assets stood at 5.977 billion yuan, with net assets attributable to shareholders at 2.32 billion yuan and a debt-to-asset ratio of 61.2% [2][8] - The cash balance at the end of the period was 1.067 billion yuan, a 40% increase from the beginning of the year, indicating strong liquidity [2][8] Future Focus - The company aims to focus on the commercialization of core products, optimize its R&D pipeline, and enhance operational efficiency through international licensing collaborations [3][10] - Key future considerations include the sustained growth of core products, progress in overseas licensing, R&D investments, and ongoing optimization of the cost structure [3][10]